Tempest Therapeutics Inc（TPST）财务数据TPSTTempest Therapeutics Inc

Evaluating the bottom line, Tempest Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -931.14%, provide a clear picture of how effectively TPST converts its operational activities into shareholder value.

In the context of the broader market, TPST competes directly with industry leaders such as TOVX and APRE. With a market capitalization of $7.60M, it holds a leading position in the sector. When comparing efficiency, TPST's gross margin of N/A stands against TOVX's 100.00% and APRE's N/A. Such benchmarking helps identify whether Tempest Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Tempest Therapeutics has shown significant financial distress, with a net income loss of $27,696,000 in Q1 2026 and a gross profit of -$22,180,000. The current ratio has dropped to 0.38, indicating liquidity issues, and the total equity has turned negative at -$1,090,000.